CVRx (NASDAQ:CVRX – Get Free Report) had its price target dropped by investment analysts at Cantor Fitzgerald to $2.00 in a report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s target price would indicate a potential upside of 229.27% from the company’s current price.
CVRX has been the subject of a number of other reports. Canaccord Genuity Group lowered shares of CVRx from a “buy” rating to a “hold” rating and cut their target price for the company from $5.00 to $2.00 in a report on Friday, November 6th. William Blair downgraded shares of CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday, November 6th. Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective for the company. in a research report on Friday, August 7th. Piper Sandler cut shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research note on Friday, August 7th. Finally, Lake Street Capital reduced their target price on shares of CVRx from $3.50 to $1.50 and set a “hold” rating on the stock in a report on Friday, November 6th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $2.70.
Check Out Our Latest Analysis on CVRx
CVRx Stock Performance
Shares of CVRX stock opened at $0.61 on Friday. The firm has a fifty day moving average price of $1.85 and a 200-day moving average price of $5.00. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71. CVRx has a 1 year low of $0.60 and a 1 year high of $10.28. The company has a market cap of $17.30 million, a price-to-earnings ratio of -0.30 and a beta of 0.81.
CVRx (NASDAQ:CVRX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The business had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $13.93 million. CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. As a group, equities analysts predict that CVRx will post -2.04 earnings per share for the current year.
Institutional Trading of CVRx
A number of large investors have recently modified their holdings of CVRX. Jump Financial LLC raised its holdings in shares of CVRx by 26.0% in the third quarter. Jump Financial LLC now owns 97,673 shares of the company’s stock valued at $171,000 after acquiring an additional 20,173 shares in the last quarter. Empowered Funds LLC bought a new position in CVRx during the 3rd quarter worth about $63,000. First Eagle Investment Management LLC bought a new position in CVRx during the 3rd quarter worth about $386,000. Russell Investments Group Ltd. increased its position in CVRx by 2,137.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 100,937 shares of the company’s stock valued at $177,000 after purchasing an additional 96,426 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in CVRx during the 3rd quarter valued at about $87,000. Hedge funds and other institutional investors own 75.27% of the company’s stock.
About CVRx
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
See Also
- Five stocks we like better than CVRx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
